4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
29 1월 2024 - 10:00PM
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company),
a leading clinical-stage genetic medicines company focused on
unlocking the full potential of genetic medicines to treat large
market diseases, today announced that it will host a live webcast
to discuss interim data from the intravitreal 4D-150 Phase 2 PRISM
clinical trial in wet AMD patients with severe disease activity and
high treatment burden, as well as provide a program update on
Monday, February 5 at 8:00 a.m. ET. Arshad M. Khanani, M.D., M.A.,
FASRS, Principal Investigator of the PRISM clinical trial, will
also present in the webcast and be available for Q&A.
Corporate Webcast Details:
Title: |
4D-150 Randomized Phase 2 Dose Expansion in Severe Disease Activity
Wet AMD with High Treatment Burden: Interim Clinical Data &
Program Update |
Date/Time: |
Monday, February 5, 2024 at 8:00 a.m. ET |
Registration: |
Link |
An archived copy of the webcast will be available for up to one
year by visiting the “Investors & Media” section of the 4DMT
website at the following link:
https://ir.4dmoleculartherapeutics.com/events.
2024 Angiogenesis, Exudation, and Degeneration
Presentation Details:
Title: |
First Interim Results (24 weeks) for the Randomized Phase 2 Dose
Expansion Stage of the PRISM Clinical Trial of 4D-150 in High Need
Patients with nAMD |
Session: |
VI: Emerging Therapies for Exudative AMD |
Date/Time: |
Saturday, February 3, 2024 (during Session VI: 3:30 to 5:00
p.m. ET) |
Presenter: |
Arshad M. Khanani, M.D., M.A., FASRS, Director of Clinical Research
at Sierra Eye Associates, Clinical Associate Professor at
University of Nevada, Reno School of Medicine |
|
|
The presentation from the Angiogenesis, Exudation, and
Degeneration 2024 Conference will also be available on the 4D
Molecular Therapeutics website under Scientific Presentations:
https://4dmoleculartherapeutics.com/pipeline/#posters-and-publications
About 4D-150 for Wet AMD
4D-150 is comprised of our customized and evolved intravitreal
vector, R100, and a transgene cassette that expresses both
aflibercept and a VEGF-C inhibitory RNAi. This dual-transgene
payload inhibits four members of the VEGF angiogenic family of
factors that drive wet AMD and DME: VEGF A, B, C and PlGF. R100 was
invented at 4DMT through our proprietary Therapeutic Vector
Evolution platform; we developed this platform utilizing principles
of directed evolution, a Nobel Prize-winning technology. 4D-150 is
designed for single, low-dose intravitreal delivery for transgene
expression from the retina without significant inflammation.
About Wet AMD
Wet AMD is a highly prevalent disease with estimated incidence
rate of 200,000 new patients per year in the United States. It is
estimated that the total prevalence of wet AMD in the major
markets, including the U.S., EU (major markets), and Japan, will be
greater than 4 million individuals in the next five years. Wet AMD
is a type of macular degeneration where abnormal blood vessels
(choroidal neovascularization or CNV) grow into the macula, the
central area of the retina. As a consequence, CNV causes swelling
and edema of the retina, bleeding and scarring, and causes visual
distortion and reduced visual acuity. The proliferation and leakage
of abnormal blood vessels is stimulated by VEGF. This process
distorts and can potentially destroy central vision and may
progress to blindness without treatment.
About 4DMT
4DMT is a leading clinical-stage genetic medicines company
focused on unlocking the full potential of genetic medicines to
treat large market diseases in ophthalmology and pulmonology.
4DMT’s proprietary invention platform, Therapeutic Vector
Evolution, combines the power of the Nobel Prize-winning
technology, directed evolution, with approximately one billion
synthetic AAV capsid-derived sequences to invent customized and
evolved vectors for use in our wholly owned and partnered product
candidates. Our product design, development, and manufacturing
engine helps us efficiently create and advance our diverse product
pipeline with the goal of revolutionizing medicine with potential
curative therapies for millions of patients. Currently, 4DMT is
advancing five clinical-stage and two preclinical product
candidates, each tailored to address rare and large market diseases
in ophthalmology, pulmonology, and cardiology. In addition, 4DMT is
also advancing programs in CNS through a gene editing partnership.
4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™,
and the 4DMT logo are trademarks of 4DMT.
All of our product candidates are in clinical or preclinical
development and have not yet been approved for marketing by the FDA
or any other regulatory authority. No representation is made as to
the safety or effectiveness of our product candidates for the
therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Katherine SmithInizio Evoke
CommsKatherine.Smith@inizioevoke.com
Investors:
Julian PeiHead of Investor Relations and Corporate
CommunicationsInvestor.Relations@4DMT.com267-644-5097
4D Molecular Therapeutics (NASDAQ:FDMT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
4D Molecular Therapeutics (NASDAQ:FDMT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024